- Home
- ACIC vs PBYI Comparison
ACIC vs PBYI Comparison
Compare ACIC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | PBYI |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.4M | 467.2M |
| IPO Year | 2007 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ACIC | PBYI |
|---|---|---|
| Price | $11.11 | $10.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 309.7K | ★ 320.0K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.76% | N/A |
| EPS Growth | ★ 39.61 | N/A |
| EPS | ★ 0.83 | 0.08 |
| Revenue | ★ $335,439,000.00 | $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.33 |
| P/E Ratio | ★ $13.38 | $122.75 |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.01 | $4.58 |
| 52 Week High | $13.06 | $10.72 |
Technical Indicators
Market Signals| Indicator | ACIC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 78.91 | 55.73 |
| Support Level | $10.98 | $9.04 |
| Resistance Level | $11.35 | N/A |
| Average True Range (ATR) | 0.32 | 0.43 |
| MACD | 0.20 | -0.00 |
| Stochastic Oscillator | 91.16 | 57.55 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.